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Abstract
Background: The localisation of AMPA and NMDA receptor subunits was studied in a model of
degeneration of cervical spinal motoneurons, the wobbler mouse. Cervical regions from early or
late symptomatic wobbler mice (4 or 12 weeks of age) were compared to lumbar tracts
(unaffected) and to those of healthy mice.
Results: No differences were found in the distribution of AMPA and NMDA receptor subunits at
both ages. Western blots analysis showed a trend of reduction in AMPA and NMDA receptor
subunits, mainly GluR1 and NR2A, exclusively in the cervical region of late symptomatic mice in the
triton-insoluble post-synaptic fraction but not whole homogenates. Colocalisation experiments
evidenced the expression of GluR1 and NR2A receptors in activated astrocytes from the cervical
spinal cord of wobbler mice, GluR2 did not colocalise with GFAP positive cells. No differences
were found in the expression of AMPA and NMDA receptor subunits in the lumbar tract of
wobbler mice, where neither motoneuron loss nor reactive gliosis occurs.
Conclusion: In late symptomatic wobbler mice altered levels of GluR1 and NR2A receptor
subunits may be a consequence of motoneuron loss rather than an early feature of motoneuron
vulnerability.
Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder affecting motoneurons in the spinal cord, brain-
stem and motor cortex and leading to denervation, mus-
cular atrophy, paralysis and premature death [1]. The
disease is sporadic in approximately 90% of cases [2] and
the correlation between the pathology and an identified
gene mutation is known only in a small percentage of
cases (2%) [3].
Glutamate-induced excitotoxicity may be one of the main
factors in ALS pathogenesis [4]. Both glial and neuronal
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glutamate transporters play a pivotal role in avoiding exci-
totoxicity by removing the excess of glutamate released
into the synaptic cleft from presynaptic neurons and con-
sequently preventing the overstimulation of post-synaptic
glutamate receptors. Evidence of abnormal glutamate
metabolism and impaired expression of the glial gluta-
mate transporter 2 (EAAT2) in ALS patients suggests that
glutamate-induced excitotoxicity plays a key role in gener-
ating this disease [5]. Glutamate overstimulation can act
through both the N-methyl-D-aspartate (NMDA) recep-
tors and the alpha-amino-3-hydroxy-5-methyl-4-isoxa-
zole propionate/kainate ionotropic (AMPA) receptors,
generating an excessive influx of Ca++ and Na+ in neurons
and the subsequent activation of damaging pathways,
leading to motoneuron death [5]. Another source of
motoneuron vulnerability involves a change of Ca++ con-
ductance in AMPA receptors. The relative Ca++ permeabil-
ity of native AMPA receptors in neurons is inversely
correlated with the rate of edited GluR2 and the differ-
ences in this Ca++ permeability between various neuronal
cell types could be an important constituent of selective
vulnerability [5]. It has been widely demonstrated that
different neuronal cell types can differ in GluR2 expres-
sion, in the rate of GluR2 editing and in the desensitisa-
tion properties of their AMPA receptors [6] and such
differences may be related to the selective vulnerability of
motoneurons in ALS. GluR2 mRNA levels in motoneu-
rons are the lowest among the human neuronal popula-
tions considered [7]. In addition, in a subset of ALS
patients, the editing of GluR2 is defective, causing
increased Ca++ permeability to the AMPA receptor [8], that
enhances Ca++-dependent pathways and leads to motone-
urons death [9].
Although these results suggest glutamate-induced excito-
toxicity is involved in ALS, it is almost impossible to verify
this in humans because of the impossibility of studying
cerebral tissues during the clinical course of the disease.
Therefore animal models of motoneuron degeneration
can provide a reliable tool for investigating alterations of
parameters potentially involved in the human disease,
mainly during the early phases.
The wobbler mouse, originally characterized and
described by Falconer [10], carries a mutation in a gene
coding for a protein involved in the retrograde transport
from endosomes to the trans Golgi network (Vps54) [11].
At the end of the symptomatic phase (12 weeks of age) the
number of motoneurons in the cervical region is reduced
by about 65%. Wobbler mice show progressive atrophy of
foreleg muscles, with marked loss of muscle strength and
motor ability.
Although several pharmacological treatments have been
tested in wobbler mice and a full ultrastructural character-
ization of degenerating motoneurons has already been
carried out [12-16], the possible role of glutamate-
induced excitotoxicity in motoneuron death in these mice
is far from clear. No changes in the GLT-1 and GLAST
glutamate transporters were reported in cervical spinal
cord at different stages of disease [17] and results on gluta-
mate receptor binding autoradiography in wobbler spinal
cord tend to vary [18,19].
To better elucidate the role of glutamate receptors in this
model of motoneuron disease, we focused on the expres-
sion and localisation of AMPA and NMDA receptor subu-
nits. We performed Western blot experiments to evaluate
the protein levels of the different AMPA (GluR1-4) and
NMDA (NR1, NR2A) receptor subunits both in whole
homogenates and in Triton-Insoluble post-synaptic Frac-
tion (TIF) [20] from cervical and lumbar spinal cord.
Since motoneurons represent only a small percentage of
the heterogeneous tissue of spinal cord, we also investi-
gated AMPA and NMDA receptor subunits by immuno-
histochemical experiments, to obtain information both
on the levels of protein expression and on the cellular
localization in motoneurons of cervical and lumbar spi-
nal cord in healthy and diseased mice at two different
phases of the disease.
Results
Immunohistochemistry for AMPA and NMDA receptors
Cervical region
GluR1
The patterns of staining for GluR1 in the whole cervical
spinal cord of four-week-old wobbler mice and healthy
littermates e shown in figure 1, panels A, I. In both sec-
tions there was marked immunoreactivity in the dorsal
horns and weak but homogenous staining in whole gray
matter; the white matter was almost unstained for GluR1.
No real differences were seen between wobbler and
healthy mice sections.
Figure 1, panels E, M, shows the distribution and localiza-
tion of GluR1 staining in motoneurons in the cervical spi-
nal cord of healthy mice (E) and early symptomatic
wobbler mice (M). The distribution of GluR1 in motone-
urons of healthy mice was detectable only outside the
nucleus possibly on the cell surface and in the cytoplasm.
Motoneurons from the cervical region of wobbler mice
showed weaker staining and a diffuse immunoreactivity
not selective to neurons, colocalisation experiments have
demonstrated to be related to glial cells (figure 3C–F); this
novel pattern of GluR1 staining was also evident in
motoneurons of 12-week-old wobbler mice (Q).
GluR2
GluR2 immunoreactivity in the cervical spinal cord of
four-week-old wobbler mice and healthy littermates isBMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
Page 3 of 12
(page number not for citation purposes)
AMPA receptor subunits in the spinal cord of control and wobbler mice Figure 1
AMPA receptor subunits in the spinal cord of control and wobbler mice. Representative photomicrographs showing 
the pattern of AMPA immunostaining in the cervical spinal cord of four-week-old healthy mice (A-D) and age-matched wobbler 
mice (I-L). Subcellular localisation of the different AMPA receptor subunits in four-week-old healthy mice is shown in panels (E-
H) Panels (M-P) show the pattern of staining in motoneurons of the cervical spinal cord from four-week-old wobbler mice. The 
distribution of GluR 1–4 in the cervical spinal cord of 12-week-old wobbler mice is shown in panels (Q, R, S, T). Scale bar, A-
D, I-L 100 µm. E-H, M-T 20 µm.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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shown in figure 1, panels B, J. GluR2 showed an intense
staining in the whole gray matter, mainly in the dorsal
horns and in neurons of ventral horns. In the anterior
horn, large neurons in the lamina IX showed intense
immunoreactivity. No marked differences were seen
between healthy mice (B) and wobbler mice (J).
The distribution and localization of GluR2 immunostain-
ing in anterior horn neurons of the cervical spinal cord in
four-week-old wobbler mice and healthy littermates is
shown in figure 1, panels F, N. Motoneurons were
intensely stained in wobbler mice (N) and healthy litter-
mates (F). The same pattern of staining for GluR2 was
seen in surviving motoneurons in 12-week-old wobbler
mice (R).
GluR3
Cervical spinal cord sections showed strong immunos-
taining for GluR3 in the dorsal horns, both in wobbler
and healthy littermates (figure 1 panels C, K). The anterior
horn showed spotty staining, mainly in the central and
lateral columns of lamina IX motoneurons. Observation
of the anterior horn at higher magnification clearly con-
firmed that this strong immunoreactivity for GluR3 was
related to large neurons.
As shown in figure 1, panels G and O, GluR3 was mark-
edly expressed in the whole surface of the cell body in
motoneurons of the cervical spinal cord and also in the
proximal region of its prolongations, likely axons. There
was no marked difference in localization, distribution and
density of staining for GluR3 in motoneurons between
wobbler mice (O) and healthy littermates (G) in either
the presymptomatic or late symptomatic stage (S).
GluR4
Staining for GluR4 was mainly localized in the dorsal
horns. In the cervical region of four-week-old wobbler
mice modest but detectable immunostaining was also
observed in the anterior horns, but in fibers more than in
cell bodies (figure 1 panels D, L). Observation of anterior
horn neurons at higher magnification clearly revealed a
marked immunoreactivity around the nuclear area and a
weaker signal in the periphery in unaffected (figure 1H),
in early (P) and late symptomatic mice (T).
NR1 and NR2A
Figure 2 shows the pattern of staining for two NMDA
receptor subunits (NR1 and NR2A) in the spinal cord of
early symptomatic wobbler mice. In wobbler mice and
healthy littermates (not shown) the staining for NR1 and
NR2A was weaker and more homogeneously diffused in
the whole grey matter than for AMPA receptor subunits.
The antibody directed against the NR1 subuni showed a
marked immunoreactivity mainly in dorsal horns and in
neurons localized in the lamina X close to the central
canal. In the ventral horns the staining was very weak and
in the lamina IX large- neurons, presumably motoneu-
rons, shoed pattern of immunoreactivity confined to the
extreme periphery of the cell, likely delimiting the plasma
membrane. No differences between affected mice and
healthy littermates have been observed either in the distri-
bution of these subunit in the different areas of spinal
cord or in the specific motoneuron staining.
Different to NR1 immunostaining the immunoreactivity
of NR2A was nearly absent in dorsal and central areas and
was mainly concentrated in ventral neurons (figure 2C).
In motoneurons the immunoreactivity for NR2A was
detectable in the surface corresponding to the cell body
and in its arborizations (figure 2D); this pattern of stain-
ing was similar in healthy mice and in motoneurons of
late symptomatic wobbler mice which are not yet degen-
erated.
Lumbar region
Immunohistochemistry experiments for AMPA and
MNDA receptor subunits in the lumbar tract of 4- and 12-
week-old wobbler and control mice showed the same pat-
terns of staining as in the cervical (data not shown). No
difference between unaffected and diseased mice were
found in this region.
Colocalisation experiments
GFAP immunostaining in the cervical region of 12-week-
old healthy mice (figure 3A) and in age-matched wobbler
mice (figure 3B) confirms that reactive gliosis was exclu-
sively present in affected mice. GFAP positive cells were
mainly localized in the anterior horn, close to the injured
area. This difference was already detectable in early symp-
tomatic wobbler mice (figure 3, panels D,H,L,P,T).
Figure 3, panels C-V, show triple staining experiments of
confocal microscopy in the lamina IX of the cervical spi-
nal cord of four-week-old wobbler mice using fluorescent
Nissl tracer to stain neurons (first column, purple), anti-
GFAP antibody to stain astrocytes (second column, red)
and specific antibodies to AMPA receptor subunits and
NR2A (third column, green). The same experiment was
carried out also in healthy mice (not shown) but the lack
of immunoreactivity for GFAP did not give us any signifi-
cant information about the glial localisation of such sub-
units in unaffected mice.
Figure 3F shows the merge between Nissl staining (C),
GFAP immunoreactivity (D) and GluR1 expression (E) in
the lamina IX in the cervical region of four-week-old wob-
bler mice. This experiment confirmed that GluR1 immu-
noreactivity was abundant in large motoneurons, with aBMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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lower profile of expression in smaller Nissl-positive cells
and strong immunoreactivity in GFAP-positive cells.
The merge between Nissl staining (G), GFAP immunore-
activity (H) and GluR2 expression (I) is shown in figure
3J. GluR2 was almost exclusively expressed in Nissl-posi-
tive cells, either in large or in small neurons, while colo-
calisation between GFAP and this subunit was very weak
and spare.
Figure 3, panels K-N, shows the staining for Nissl (K),
GFAP (L), GluR3 (M) and the merge among the three col-
ours (N). GluR3 was abundantly expressed in almost all
neurons and also colocalised with GFAP-positive cells.
GluR4 immunoreactivity, figure 3Q, was very low and
confined to large Nissl-positive neurons (O, R), whereas
GFAP-positive cells (P) showed no colocalisation with
this subunit (R). Interestingly, colocalisation experiments
in the white matter of anterior horn in the same section,
figure 3, panels W-Z, showed a clear pattern of colocalisa-
tion (Z) between GFAP-positive radial glia (X) and GluR4
(Y).
Figure 3, panels S-V, shows the expression of NR2A (U),
Nissl (S), GFAP (T) and the merge among the three images
(V). Although NR2A seemed to show a lower staining in
neurons compared to single immunohistochemical exper-
iments (figure 2C,D) there was a clear colocalisation
between this subunit and GFAP-positive cells (figure 3V).
To clarify the subcellular distribution of AMPA receptor
subunits, double staining experiments were done in the
cervical region of four-week-old wobbler mice and
healthy littermates.
Figure 4, panels A, D, G, shows high magnification pic-
tures of Nissl-positive large neurons localized in lamina
IX, presumably motoneurons. Due to the abundance of
cytoplasmic ribonucleic acids in neurons Nissl staining
was not only a reliable marker to recognize neurons but
also to selectively stain the cytoplasm. Therefore the
merge between GluR1 (B), GluR2 (E) or GluR3 (H) and
Nissl-positive neurons allowed to show the expression of
AMPA receptor subunit in close proximity to the axons
and dendrites. The merge between Nissl and each single
AMPA receptor subunit, figure 4, panels C, F, I, shows that
the immunoreactivity for GluR1 (C), GluR2 (F) and
GluR3 (I) was not only confined to perykarion but it was
also evident in the proximal part of its arborizations mor-
phologically similar to axon hillock.
Western blotting analysis
AMPA and NMDA receptor subunit protein levels were
examined by western blot analysis in whole homogenate
and TIF prepared from cervical and lumbar spinal cord of
4- and 12-week-old wobbler mice and healthy littermates.
Protein yields were similar in TIF from all groups and the
same amount of whole homogenate and TIF proteins was
applied to SDS-gel and electroblotted. At both stages of
the disease no differences between wobbler mice and
NMDA receptor subunits in spinal cord of wobbler mice Figure 2
NMDA receptor subunits in spinal cord of wobbler mice. Representative photomicrographs showing NR1 (A,C) and 
NR2A (B,D) immunostaining in the cervical spinal cord of four-week-old wobbler mice (B). Scale bar, A, B 100 µm. C, D 20 
µm.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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ionotropic glutamate receptors in the lamina IX in the cervical spinal spinal cord of four-week-old wobbler mice Figure 3
ionotropic glutamate receptors in the lamina IX in the cervical spinal spinal cord of four-week-old wobbler 
mice. UPPER PANELS. Representative photomicrographs showing the patterns of GFAP immunostaining in the cervical spinal 
cord region of 12-week-old mice (A) and age-matched symptomatic wobbler mice (B). CENTRAL PANELS (C-V). Triple stain-
ing experiments using Nissl (C, G, K, O, S, purple colour) GFAP (D, H, L, P, T, red colour) and GluR 1–4 or NR2A (E, I, M, Q, 
U, green colour) in the anterior horn of four-week-old wobbler mice. The merge between the three different colours is shown 
in panels F, J, N, R, V. LOWER PANELS (W-Z). Triple staining showing Nissl (W), GFAP (X), GluR4 (Y) and the merge 
between the three different colurs (Z), in the white matter in the anterior region of the cervical spinal cord, four-week-old 
wobbler mouse. Scale bar, A-B, 100 µm. C-V, 30 µm. W-Z 40 µm.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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healthy littermates were found in the levels of expression
of any proteins in the homogenate fractions, in either
lumbar or cervical spinal cord region (figure 5). Altera-
tions in the protein levels in the TIF were observed in late
symptomatic wobbler mice aged 12 weeks (figure 5), but
not in early symptomatic mice.
The quantification of the optical densities of proteins in
whole homogenate fraction and TIF, performed in two
different experiments from the cervical region of 12-week-
old wobbler mice, is shown in figure 5. Mean values from
wobbler mice were expressed as percentage of the mean
values obtained from healthy littermates.
cellular localization of GluR 1–3 subunits in motneurons in the cervical spinal spinal cord of four-week-old wobbler mice Figure 4
cellular localization of GluR 1–3 subunits in motneurons in the cervical spinal spinal cord of four-week-old wob-
bler mice. LEFT COLUMN (A, D, G). Panels A, D, G, show the profile of Nissl staining (red) in large neurons localized in the 
lamina IX of the cervical spinal cord of four-week-old wobbler mouse. CENTRAL COLUMN (B, E, H). Central panels show the 
staining for the three different AMPA receptor subunits, GluR1 (B), GluR2 (E), GluR3 (H) (green) in lamina IX of the cervical 
spinal cord of four-week-old wobbler mouse. RIGHT COLUMN (C, F, I). Panels C, F, I show the localisation of GluR1 (C), 
GluR2 (F) and GluR3 (I) in Nissl-positive large neurons of the lamina IX. Jellow staining is the area of merge between Nissl and 
AMPA receptor subunits. Scale bar, 15 µm.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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Although statistical comparison cannot be performed, the
quantification showed that there was a strong reduction
for NR2A and GluR1 in the TIF, but not in whole homoge-
nate. In TIF of 12-week-old wobbler mice GluR2 and
GluR3 were reduced to a lower extent.
In the lumbar spinal cord there was no change of gluta-
mate receptor subunits for the TIF compartment even
though a surprising increase in NR2A was detected in lum-
bar region of four-week-old of wobbler mice.
GFAP levels in whole homogenates of cervical spinal cord
in either 4- and 12-week-old wobbler mice are markedly
increased [17], however no GFAP expression in TIF sam-
ples was found from cervical and lumbar spinal cord of
wobbler mice and healthy littermates at four and 12
weeks of age (data not shown).
Discussion
NR2A and GluR1 receptor subunits in TIF samples from
the cervical spinal of cord wobbler mice decreased only in
the late stage of the disease, when the two thirds of
motoneurons were lost, but not in the early stage. This is
an important point of discussion because between the
fourth and fifth weeks of life the rate of motoneuron
death peaks in the cervical region of wobbler mice (25%
of total motoneurons disappears), but no simultaneous
alteration in the expression of AMPA and NMDA recep-
western blotting analysis and quantification of the percentage of AMPA and NMDA receptor subunits expression in spinal cord  of wobbler mice Figure 5
western blotting analysis and quantification of the percentage of AMPA and NMDA receptor subunits expres-
sion in spinal cord of wobbler mice. Representative immunoblot from cervical spinal cord samples from 12-week-old 
healthy mice and age-matched wobbler mice. Left column: whole spinal cord homogenates. Right column: spinal cord TIF. 
Quantification of the mean values of immunodensity for CaMK, AMPA and NMDA receptor subunits, obtained from the cervi-
cal spinal wobbler mice in whole spinal cord homogenates (Homo) and in TIF. Data are representative of two independent 
experiments on two different homogenate preparations of four pooled animals for each group and replicated two times in each 
homogenate preparation. Values reported represent the percentage of the mean values of immunodensity obtained in 12-
week-old wobbler mice compared to the levels measured in healthy littermates and normalized to 100. Both preparations sam-
ples were analyzed by Western blot analysis with CaMKII, GluR1, GluR2, GluR3, GluR4, NR1, and NR2A antibodies. The same 
amount of protein was loaded per lane.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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tors in post-synaptic densities are present. The lack of low-
ering of AMPA and NMDA receptor subunits levels in TIF
from early symtpomatic wobbler mice, when at least 25%
of motoneurons are lost, might be to due to the fact that
post-synaptic densities are not only related to motoneu-
rons, and our immunohistochemical experiments clearly
showed that AMPA and NMDA receptor subunits are
expressed in almost all neuronal populations, particularly
the dorsal horn neurons.
In addition, immunohistochemical studies indicated that
the localisation and the distribution of AMPA and NMDA
receptor subunits in the whole cervical region of both
early and late symptomatic wobbler mice was no different
from that of healthy littermates. It is of interest that the
decrease of AMPA and NMDA receptor in TIF was not
found in the lumbar spinal cord region, in either early or
late stages of the disease, where motoneurons were not
lost. These observations suggest that the decrease in
GluR1 and NR2A receptor subunits in TIF from the cervi-
cal spinal cord of late symptomatic wobbler mice might
be a consequence of motoneuron loss. Differently from
the TIF, the whole homogenate fraction from cervical
region of 12-week-old wobbler mice and healthy litterma-
tes contained the same amounts of AMPA and NMDA
receptor subunits. However, TIF includes glutamate recep-
tors expressed in the post-synaptic densities of spinal neu-
rons, and the glial component was nearly absent in this
preparation [20,21]. Our study using triple-immunofluo-
rescence experiments showed that GluR1 and NR2A were
highly expressed in activated astrocytes, and marked reac-
tive gliosis selectively occurs in the cervical spinal cord of
wobbler mice during the progression of the disease [17].
Thus, in the whole homogenate from affected region, the
expression of GluR1 and NR2A receptors in activated
astrocytes may partially mask the difference of these sub-
units found in TIF.
Although in the cervical region of wobbler mouse there is
no evidence of increased glutamate release from the corti-
cospinal tract, a defective mechanism regulating gluta-
mate/glutamine synthesis and/or influx or efflux in
purified cultures of astrocytes from symptomatic wobbler
mice has been reported [22]. Our study evidenced that
astrocytes in the cervical region of wobbler mice lack the
Ca++ impermeable AMPA receptor subunits (GluR2) and
suggests an interesting scenario about neurons-glia cross-
talk in wobbler motoneuron disease. Further investiga-
tion of the susceptibility to excitotoxic agents in
motoneurons from the cervical spinal cord of wobbler
mice would help to characterize the involvement of gluta-
mate-induced excitotoxicity in this model.
A less direct but nevertheless reliable approach to study
the different sensitivity of AMPA receptors in wobbler
mice is chronic treatment with AMPA antagonists.
Their protective role has been reported in different models
of motoneuron degeneration. The non-competitive
AMPA antagonist ZK187638 significantly reduced the
symptoms of neuromuscular deficit and improved the
motor behavioural impairment in both SOD1G93A and
mnd mice, and extended the survival of SOD1G93A trans-
genic mice [23]. In these latter, the competitive AMPA
antagonist RPR119990 significantly improved muscle
strength and prolonged survival [24]. We did not find
beneficial effects after chronic treatment of wobbler mice
with RPR119990 on the progression of the disease, the
rate of motoneuron loss and biceps atrophy [25].
Regarding the role of NMDA receptor-mediated injury in
wobbler mice, it has been reported that treatment with the
non-competitive NMDA receptor antagonist +-5-methyl-
10,11-dihydro-5H-dibenzo(a,d)cyclopheten-5,10-imine
maleate (MK801), did not delay the progression of the
disease [14]. Our characterization seems to be in accord-
ance with this result, suggesting that altered expression of
NMDA receptor subunits is not involved in the early
symptomatic phase of the disease.
Although further experiments with other AMPA and
NMDA receptor antagonists are required to confirm our
results, this pharmacological evidence adds relevance to
the results reported in the present study and makes even
more convincing that no alteration in glutamate receptors
is involved in the wobbler mouse motoneuron disease.
Conclusion
The main evidence from this study is that the decrease in
the amount of GluR1 and NR2A receptor subunits in TIF
in late symptomatic wobbler mice is not related to an
early reduction in the expression of these subunits in
degenerating motoneurons, but more likely is related to
the reduction in motoneuron number at the late stage of
the disease.
Methods
Animals
Wobbler mice and homozygous healthy littermates (NFR/
wr strain, NIH, Animal Resources, Bethesda, USA) were
bred at Charles River Italia (Calco, Lecco, Italy). Mice were
maintained at 21 ± 1°C with relative humidity 55 ± 10%
and a 12-hour light/dark cycle. Food (standard pellets)
and water were available ad libitum.
Procedures involving animals and their care were con-
ducted in conformity with the institutional guidelines
that are in compliance with national (D.L. n° 116, G.U.BMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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suppl. 40, 18 Febbraio 1992, circolare n° 8, G.U. 14
Luglio 1994) and international laws and policies (EEC
Council Directive 86/609, OJ L 358, 1, December 12,
1987; NIH Guide for the Care and Use of Laboratory Ani-
mals, US National Research Council 1996).
Experimental animals
In order to identify wr/wr homozigous mice, healthy
homozygous +/+ and healthy heterozygous wr/+ litterma-
tes, a genotyping analysis was performed. An Alu I restric-
tion polymorphism of a Cct 4 amplification product was
used for testing the allelic status at the wr locus (Rathke-
Hartlieb 1999).
Early ymptomatic wobbler mice can be easily recognized
by their phenotypical features. From 3rd week of age, wob-
bler mice begin to growth slower than healthy littermates
and, only a week later, they are 40–50% (also depending
on the strain) smaller that their age-matched healthy
mice. At the 3rd–4th week wobbler mice already show an
altered position of fingers, wrists and paws. This alteration
derives from muscular atrophy and produces unsteady
gait with a discrete tremor. Afterwards, instability and
wobbling of the gait develop progressively thus producing
alteration in walking that is a typical feature of motor
impairment occurring in the wobbler mice. As previously
proposed by Kozachuk and colleagues, these two parame-
ters of abnormalities can be useful to determine the
degree of clinical worsening during this phase of the dis-
ease [26].
Immunohistochemistry
To ensure optimal quality of spinal cord tissues for histo-
chemical determinations, tissues were fixed following the
transcardial perfusion method using a solution of 4%
paraformaldehyde (w/v) in 0.1 M phosphate buffered
saline (PBS) (pH 7.4). After perfusion, the isolated back-
bone was postfixed for 3 hours at 4°C in the same solu-
tion. After postfixation the spinal cord was gently
removed from the vertebral column and cryoprotected by
three serial 2-h incubations at 4°C, in 0.1 M PBS, contain-
ing increasing concentrations of sucrose (10%, 20% and
30%), then dipped in cooled isopentane (-35°C to -
45°C) to quickly freeze them.
For free-floating immunohistochemistry, micrometric
sections (30 µm thick) were placed in plate wells contain-
ing PBS, then rinsed three times (10 min each) to remove
the Tissue-Tek® O.C.T.™ solution used to surround and
cover spinal tissues and ensure optimal cutting.
Before incubation with specific antibodies directed
against the GluR-1, 2, 4 subunits, the same experimental
procedure was used. After three rinses in 0.1 M PBS, sec-
tions were preincubated in PBS containing 5% foetal
bovine serum and then incubated in PBS containing 0.5%
Triton-X100 for 1 hour at room temperature. For GluR3
immunostaining, preincubation in PBS containing 0.5%
albumin for 24 hours at 4°C was done to reduce non-spe-
cific staining.
For all AMPA receptor subunits, sections were incubated
overnight at 4°C in a solution of PBS containing 0.1% Tri-
ton-X100 and 3% FBS with the specific antibodies: anti-
rabbit polyclonal antibody raised against GluR-1
(AB1504, Chemicon International, Temecula, CA, US;
1:200); anti-mouse monoclonal antibody raised against
GluR-2 (MAB397, Chemicon International, Temecula,
CA, US; 1:1000); anti-goat polyclonal antibody raised
against GluR-3 (sc-7613, Santa Cruz Biotechnology, Santa
Cruz, CA, US; 1:400) and anti-rabbit polyclonal antibody
raised against GluR-4 (AB1508, Chemicon International,
Temecula, CA, US; 1:50). For the NMDA receptor we used
an anti-mouse monoclonal NR1 antibody (Catatolg No
32-0500, Zymed, Invitrogen, Carlsbad, CA, US; 1:100)
and an anti-rabbit polyclonal NR2A antibody (Molecular
Probes, Invitrogen, Carlsbad, CA, US; 1:100).
After incubation with the primary antibody and three
rinses in PBS at room temperature, all the sections were
incubated for 2 hours at room temperature in PBS con-
taining 1% FBS and the appropriate secondary antibody
(1:100).
For each AMPA and NMDA receptor subunit, after incuba-
tion with the secondary antibody the sections were rinsed
three times (5 min) then incubated for 1 hour in a solu-
tion containing 1% avidin and biotinylated horseradish
peroxidase (ABC kit) in PBS 0.1 M, pH 7.4. After one rinse
in PBS and two rinses in Tris buffered saline (TBS) 0.1 M,
pH 7.8–8.3, the sections were incubated for a few minutes
in TBS containing 0.5% diamminobenzidine (DAB) (w/v)
and H2O2 (0.6 µL for 1 mL of solution, was added just
before application). As DAB is a photosensitive molecule,
it was dissolved and stored in a dark vial until incubation.
In order to avoid possible false positive results control
experiments were done using the primary or the second-
ary antibodies alone. All experiments did not produce
staining in tissues examined.
Immunofluorescence
For colocalisation experiments to characterize AMPA and
NR2A receptor subunit expression in astrocytes and neu-
rons in the cervical spinal cord of four-week-old wobbler
mice and healthy littermates perfused samples were sec-
tioned at a thickness of 15 µm. As either anti-GFAP anti-
body or anti-NR1 antibody are monoclonal anti-mouse
we could not perform colocalisation experiments among
these two proteins. For immunofluorescence experimentsBMC Neuroscience 2006, 7:71 http://www.biomedcentral.com/1471-2202/7/71
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the following antibodies were used: (rabbit anti-GluR1
polyclonal antibody AB-10129, Immunological Sciences,
Roma, IT, 1:200), (rabbit anti-GluR2 polyclonal antibody
AB-10699, Immunological Sciences, Roma, IT, 1:200),
(goat anti-GluR3 polyclonal antibody sc-7613, Santa Cruz
Biotechnology, Santa Cruz, CA, US; 1:400) (rabbit anti-
GluR4 polyclonal antibody AB-10122, Immunological
Sciences, Roma, IT, 1:50), (rabbit anti-NR2A polyclonal
antibody AB-10675, Immunological Sciences, Roma, IT,
1:200). All antibodies were incubated as reported in the
immunohistochemical methods section. Secondary anti-
bodies (Alexa-488, Molecular Probes, 1:1000) were incu-
bated for 2 h at room temperature. All sections were
incubated using a specific marker for astrocytes (anti-
mouse monoclonal GFAP antibody, MAB-12029 Immu-
nological Sciences, Roma, IT, 1:5000) at a dilution of. The
secondary antibody (Alexa-Cy5 conjugated, Molecular
Probes) was used to visualize astrocyte staining. For Nissl
immunofluorescence, sections were incubated 30 min
with 530–615 NeuroTrace Fluorescent Nissl reagent
(Molecular Probes, 1:100) at room temperature.
Sections were observed with an Olympus Fluoview micro-
scope BX61 with confocal system FV500. Images were
pseudocolored (red for the GFAP-associated staining and
green for the AMPA and NMDA receptor associated stain-
ing, purple for Nissl-associated staining) and the signal
obtained from the three different channels was automati-
cally merged by Olympus fluoview software.
Western blot analysis
Subcellular fractionation of spinal cord tissue was done as
previously reported, with minor modifications [21]. Two
different preparations, whole homogenate and TIF, were
obtained using four pooled animals for each group. Cer-
vical and lumbar spinal cord were homogenized in ice-
cold 0.32 M sucrose containing 1 mM Hepes, 1 mM
MgCl2, 1 mM EDTA, 1 mM NaHCO3, 0.1 mM PMSF, pH
7.4, with complete sets of protease inhibitors (Com-
plete™, Roche Diagnostics, Basel, Switzerland) and phos-
phatase inhibitors (Sigma-Aldrich; Saint Louis, MO, US).
The homogenized tissue was centrifuged at 1,000 × g for
10 min. The supernatant (S1) was centrifuged at 13,000 ×
g for 15 min to obtain a crude membrane fraction (P2
fraction). The pellet was re-suspended in 1 mM Hepes +
Complete™ in a glass-glass Potter apparatus and centri-
fuged at 100,000 × g for 1 h. The pellet (P3) was resus-
pended in buffer containing 75 mM KCl and 1% Triton-
X100 and centrifuged at 100,000 × g for 1 h. The final pel-
let (P4) was homogenized in a glass-glass Potter apparatus
in 20 mM Hepes. Then an equal volume of glycerol was
added and this fraction, referred to as TIF, was stored at -
80°C until processing. TIF was used instead of the classi-
cal post-synaptic density (PSD) because the amount of
starting material was very limited. The protein composi-
tion of this preparation was, however, carefully tested for
the absence of presynaptic markers (e.g. synaptophysin)
[21]. Nitrocellulose papers were blocked with 10% albu-
min in TBS, and incubated for 2 h at room temperature
with the primary antibodies NR1 (diluted 1:1000), NR2A
(1:1000), GluR1 (1:2000), GluR2 (1:1000), GluR3
(1:2000), GluR4 (1:2000), alphaCaMKII (Chemicon
International, Temecula, CA, US; 1:3000) in TBS contain-
ing 3% albumin. To avoid any difference of interpretation
from the results of immunohistochemical experiments
and western blot analysis the same batches for AMPA and
NMDA receptor antibodies were used for both. After
extensive rinsing in 0.1% TBS/Tween, the nitrocellulose
papers were incubated with horseradish peroxidase-con-
jugated secondary antibodies [goat anti-rabbit, for poly-
clonal antibodies, dilution 1:10000 (Pierce
Biotechnology Inc., Rockford, IL, U.S.); goat anti-mouse,
for monoclonal antibodies, dilution 1:20000 (Pierce Bio-
technology Inc., Rockford, IL, U.S.)] and the antigen-anti-
body complex was revealed by enhanced
chemiluminescence (ECL; Amersham International, Little
Chalfont, Buckinghamshire, UK).
Densitometric measurement
Optical density was quantified using the AIS image ana-
lyzer (Imaging Research Inc., Ontario, Canada).
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